Search
Capivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalTherefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative
Patisiran
go.drugbank.com/drugs/DB14582ApprovedIt is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … The approval for Onpattro was granted to Alnylam Pharmaceuticals, Inc. in August of 2018. Onpattro has been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations.
Chlorpheniramine
go.drugbank.com/drugs/DB01114ApprovedInvestigationalOne of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine.
Mixtures: CO-EXALIV, CO-EXALIVCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27264] Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms.[A27263] … Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling
Adagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigational[L43847] In December 2022, the FDA granted accelerated approval to adagrasib for the treatment of KRAS<sup>G12C</sup>-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic … [A187559] Adagrasib targets KRAS<sup>G12C</sup>, one of the most common KRAS mutations, at the cysteine 12 residue and inhibits KRAS-dependent signalling.
Pyrimethamine
go.drugbank.com/drugs/DB00205ApprovedInvestigationalVet approvedOne of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalIn September 2015, lusutrombopag received its first global approval in Japan to reduce the need for platelet transfusion in adults with chronic liver disease and thrombocytopenia who are schedule to undergo … In two randomized, double-blind, placebo-controlled trials, patients with chronic liver disease and severe thrombocytopenia who were undergoing an invasive procedure with a platelet count less than 50
Imelasomeran
go.drugbank.com/drugs/DB17090ApprovedInvestigationalImelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine.
alpha-Tocopherol succinate
go.drugbank.com/drugs/DB14001ApprovedNutraceuticalVet approvedNevertheless, vitamin E is known to be a fat-soluble antioxidant that has the capability to neutralize endogenous free radicals. … Alpha-tocopherol succinate is subsequently most commonly indicated for dietary supplementation in individuals who may demonstrate a genuine deficiency in vitamin E.
Mixtures: Swiss Total One, Strovite One CapletsBelantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[L53673] Later that year in October of 2025, belantamab was granded full approval by the FDA for the a similar indication to the Health Canada one. [L54331] … In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.